Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (December 2017)

Friday, February 16, 2018

In 2017, Russia imported 620.4 bln worth of pharmaceutical drugs (free circulation prices plus VAT), which is 4.4 higher than that of the same period last year. Ready-made drugs has the biggest share, with an 8.6% increase over the year and the total import volume amounting to 524.9 bln RUB. In-bulk products account for 95.5 bln RUB with a 13.9% decrease.

December showed a reverse trend. While the import volume in monetary terms had risen only by 3% and amounted to 52.5 bln RUB in November, the import of in-bulk products has increased by 16% since December 2016. The total import volume of in-bulk products amounts to 9.9 bln RUB, which is a good result considering the circumstances.

The import of ready-made pharmaceuticals in physical terms amounts to more than 2 bln units or 36.4 bln minimum dosage units (MDU). While the long-term growth rate of import of packaged products is positive (+4.1%), it is negative when calculating in MDU (-3.3%). Despite the decrease in imports in monetary terms, in-bulk imports have been growing steadily (+6.1% when calculating in MDU). The total volume of import of ready-made and in-bulk pharmaceuticals has reached 41 bln MDU, with a 2.3% decrease.

British pharmaceutical companies contributed the most to imports of packaged products. The import of ready-made British pharmaceuticals has risen by 26% in 2017. The most prominent companies are Reckitt Benckiser (+40%), which benefited from importing Nurofen and Strepsils, and Procter & Gamble (+32%), benefiting from Vicks Active SymptoMax imports.

Read more about pharmaceutical drug import to Russia (November performance) here:

Dynamic of pharmaceutical drug import to Russia (including homeopathy), CIP prices, RUB (January 2016 – December 2017)